CSF1 and hepatocellular carcinoma: Other strategies targeting the CSF1/CSFR1 axis like CSF1R blockade by PLX3397, an inhibitor for CSF1R tyrosine kinase, have shown to inhibit tumour progression in mouse models of HCC by shifting the polarization of TAMs [41].